Fingolimod - MS Research Australia

Fingolimod

Fingolimod

Administration Route: Oral
Injection site:
Frequency: Daily tablet
TGA approval date: Jan 2011
PBS listed: Yes
Mechanism of action By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes. This redistribution reduces the infiltration of pathogenic lymphocyte cells into the central nervous system where they would be involved in nerve inflammation and nervous tissue damage.
%reduction in relapse rate, impact of progression 55% RRR in annual relapes rate,82% RRR for new Gad Lesions, 75% RRR new T2 lesions, 30% RRR disability
Pregnancy Category D
Safe in Pregnancy suspected to cause or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage.
Breastfeeding (information predominatly from  LACTMED database) Because there is no published experience with fingolimod during breastfeeding, it should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.
Monitoring requirements Heart monitoring following 1st dose
Potential side effects (not a comprehensive list) Most common adverse reactions (incidence ≥10% and > placebo): Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity
Manufacturer Novartis
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search